The bacterial disease burden in India is among the highest in the world, and hospital-acquired infections are of particular concern. These infections pose a great risk to the timely recovery of patients and are associated with high mortality rates. As a result, critical care medicines play a vital role in reducing morbidity and mortality. In addition, critical care patients have life-threatening conditions requiring healthcare professionals to often use a multi-pronged treatment approach that can affect the cost of daily therapy.
To satisfy the unmet medical needs of seriously ill patients in intensive care units, Mylan India launched its Critical Care division in 2014, with several high quality, affordable antifungal, antibacterial and anticoagulant therapies. The portfolio includes AmBisome®, a leading antifungal product manufactured by Gilead and marketed by Mylan in India. AmBisome is used to treat life-threatening, systemic fungal infections and the parasitic disease visceral leishmaniasis. The product is widely accepted by hematologists, oncologists, infectious disease specialists and intensivists for the treatment of suspected or definitive systemic fungal infections.